Drugs / MSC-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06446050 | Jun 2023 → Dec 2026 expected | colorectal cancer | Shanghai East Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06446050 ↗ |
| Modality | Cell therapy | “human umbilical cord-derived allogenic mesenchymal stem cells (MSCs) engineered to express antitumor chemokine and co-stimulatory molecule” NCT06446050 ↗ |
| Route | Intravenous | “administered intravenously” NCT06446050 ↗ |